Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.
about
Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B.Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives.Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits.In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188Clinical and experimental advances in treatment of visceral leishmaniasis.The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamstersToxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats.Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin.Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.Nanostructured delivery systems with improved leishmanicidal activity: a critical review.Antifungal Efficacy of Amphotericin B against Dermatophytes and its Relevance in Recalcitrant Dermatophytoses: A Commentary.Significance of algal polymer in designing amphotericin B nanoparticles.
P2860
Q28369040-C6DFEBBA-9905-41EA-AD6A-0E0432090CB6Q33977623-12919C3B-94A8-472C-8890-1AE2035D8E27Q33978764-A7DC2808-85B4-4898-9786-DD47025FC583Q33980296-50A1EF10-A8EA-4F6D-B1EA-F6872176453DQ33982648-0A860690-50BB-483C-9B91-8C0C16ADDC1EQ33997532-86A7E723-A856-42B2-A9EF-5818ADAF0AE4Q34141596-3E17139E-0306-4864-AA2D-588919F075A4Q34230457-BBC893BA-FF43-470A-B85A-7CC6EC133118Q35168703-4292B9F9-39FC-4B35-9D25-243D6ACEE611Q35741989-E1893E19-D8B6-458D-847F-751F6B6A5252Q39473415-7CFBBCE8-A203-48C0-A00A-7DAB85E50BA3Q39478331-EEBA1305-DB43-4511-8203-7469BDA860AFQ39954346-EEE5062D-4136-4A7E-BBA9-5AEE87E8A88CQ40099567-77B242AF-FA0A-48A4-BFB9-84FB348C1CB2Q52592738-FE11CE96-22CD-4805-84E1-357171790FDAQ54917788-1FE219E6-1A69-4126-9EEB-50282CB7B085
P2860
Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.
description
1997 nî lūn-bûn
@nan
1997 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Comparison of the efficacies o ...... murine visceral leishmaniasis.
@ast
Comparison of the efficacies o ...... murine visceral leishmaniasis.
@en
type
label
Comparison of the efficacies o ...... murine visceral leishmaniasis.
@ast
Comparison of the efficacies o ...... murine visceral leishmaniasis.
@en
prefLabel
Comparison of the efficacies o ...... murine visceral leishmaniasis.
@ast
Comparison of the efficacies o ...... murine visceral leishmaniasis.
@en
P2093
P2860
P356
P1476
Comparison of the efficacies o ...... murine visceral leishmaniasis
@en
P2093
P2860
P304
P356
10.1128/AAC.41.10.2089
P407
P577
1997-10-01T00:00:00Z